ALX Oncology

80 articles with ALX Oncology

• ALX Oncology Appoints Itziar Canamasas, Ph.D., to its Board of Directors

  4/12/2022

  ALX Oncology Holdings Inc. today announced the appointment of Itziar Canamasas, Ph.D., to its Board of Directors (the “Board”) effective April 11, 2022.

• ALX Oncology Announces First Patient Dosed in ASPEN-06, a Phase 2/3 Study of Evorpacept for the Treatment of Patients with Advanced Gastric or Gastroesophageal Junction CancerPhase 2/3 study initiated in collaboration with Eli Lilly and Company

  3/2/2022

  ALX Oncology Holdings Inc. today announced the first patient has been dosed in the Phase 2/3 ASPEN-06 study evaluating the combination of evorpacept, a next generation CD47 blocker, and CYRAMZA ® (ramucirumab).

• ALX Oncology Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Clinical Development and Operational Highlights and Upcoming Milestones

  2/28/2022

  ALX Oncology Holdings Inc., (“ALX Oncology”) (Nasdaq: ALXO) a clinical-stage immuno-oncology company developing therapies that block the CD47 checkpoint pathway, today reported financial results for the fourth quarter and year ended December 31, 2021 and provided clinical development and operational highlights.

• ALX Oncology Receives U.S. FDA Orphan Drug Designation for Evorpacept for the Treatment of Patients with Gastric Cancer and Gastroesophageal Junction Cancer

  1/27/2022

  ALX Oncology Holdings Inc. today announced that the U.S. Food and Drug Administration (“FDA”) granted orphan drug designation (“ODD”) to evorpacept, a next-generation CD47 blocker, for the treatment of patients with gastric cancer and gastroesophageal junction cancer (collectively “GC”).

• ALX Oncology Provides Corporate Update and Highlights Key Milestones in 2022

  1/10/2022

  ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company developing therapies that block the CD47 checkpoint pathway, provided a corporate update and highlighted key milestones anticipated in 2022.

• ALX Oncology to Present at the 40th Annual J.P. Morgan Healthcare Conference

  1/4/2022

  ALX Oncology Holdings Inc., (“ALX Oncology”) (Nasdaq: ALXO), today announced that Jaume Pons, Ph.D., Founder, President and Chief Executive Officer, will virtually present a company overview at the 40th Annual J.P. Morgan Healthcare Conference on Tuesday, January 11 at 10:30 am ET.

• ALX Oncology Announces Initial Data from ASPEN-02, the Ongoing Phase 1 / 2 Study of Evorpacept in Combination with Azacitidine, Demonstrating Safety and Preliminary Activity in Patients with Myelodysplastic Syndrome

  12/12/2021

  ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company developing therapies to block the CD47 checkpoint pathway, announced the presentation of initial clinical data from its ongoing trial evaluating evorpacept in combination with azacitidine for the treatment of patients with previously untreated higher-risk or relapsed or refractory myelodysplastic syndrome.

• ALX Oncology Reports Third Quarter 2021 Financial Results and Provides Clinical Development and Operational Highlights

  11/11/2021

  ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company developing therapies that block the CD47 checkpoint pathway, reported financial results for the third quarter ended September 30, 2021 and provided clinical development and operational highlights.

• ALX Oncology Announces Updated Data from Ongoing Clinical Trial (ASPEN-01) of Evorpacept Showing Emerging Clinical Benefit in Survival-Based Endpoints in Patients with Advanced Solid Tumors

  11/9/2021

  ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company developing therapies to block the CD47 checkpoint mechanism, announced updated results from ASPEN-01, an ongoing evorpacept phase 1b study, evaluating patients with solid tumor malignancies at the Society for Immunotherapy of Cancer’s 36th Anniversary Annual Meeting [abstract 498].

• ALX Oncology to Present New Evorpacept Clinical Data in Myelodysplastic Syndromes at 63rd ASH Annual Meeting

  11/4/2021

  ALX Oncology Holdings Inc., today announced the Company will be presenting early clinical data from ASPEN-02, its ongoing Phase 1/2 study evaluating evorpacept in combination with azacitidine for the treatment of myelodysplastic syndromes (“MDS”) in a poster presentation at the 63rd American Society

• ALX Oncology Announces Upcoming Virtual Investor Conference Participation - Nov 02, 2021

  11/2/2021

  ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company developing therapies that block the CD47 checkpoint pathway, announced that Jaume Pons, Ph.D., Founder, President and Chief Executive Officer and other senior executives, will participate in four upcoming virtual investor conferences.

• ALX Oncology Announces First Patient Dosed in ASPEN-05, a Phase 1/2 Study of Evorpacept in Combination with Venetoclax and Azacitidine in Patients with Acute Myeloid LeukemiaSecond study of evorpacept in patients with myeloid malignancies

  10/21/2021

  ALX Oncology Holdings Inc., (“ALX Oncology”) (Nasdaq: ALXO), a clinical-stage immuno-oncology company developing therapies that block the CD47 checkpoint pathway, today announced the first patient has been dosed in the Phase 1/2 ASPEN-05 study evaluating the combination of evorpacept, a next-generation CD47 blocker, with venetoclax and azacitidine for the treatment of patients with acute myeloid leukemia (“AML”).

• ALX Oncology Strengthens Immuno-Oncology Pipeline with Acquisition of ScalmiBio

  10/7/2021

  Acquisition adds novel and proprietary SHIELD platform for conditional activation of antibodies in tumor microenvironment and proprietary cytotoxic payloads for antibody drug conjugates

• ALX Oncology Announces Four Abstracts Accepted for Presentation at the Society for Immunotherapy of Cancer (SITC) 36th Annual Meeting

  10/1/2021

  ALX Oncology Holdings Inc., (“ALX Oncology” or the “Company”), a clinical-stage immuno-oncology company developing therapies to block the CD47 checkpoint mechanism, today announced that four abstracts have been accepted for presentation at the SITC 36th Annual Meeting in Washington D.C. from November 10 –14, 2021.

• ALX Oncology Announces Initiation of Investigator-Sponsored Trial of Evorpacept (ALX148) in Patients with Indolent and Aggressive Non-Hodgkin Lymphoma-- Phase 1/2 study conducted at The University of Texas M.D. Anderson Cancer Center

  9/16/2021

  ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company developing therapies that block the CD47 checkpoint pathway, announced the initiation of a Phase 1/2 investigator-sponsored trial of evorpacept, a next generation CD47 blocker, in combination with rituximab and lenalidomide for the treatment of patients with indolent and aggressive non-Hodgkin lymphoma.

• 

  Lightstone Increases High-Impact Technologies Portfolio with $375M in New Funding

  9/14/2021

  ​Lightstone Ventures recently announced the closing of Lightstone Ventures III, securing $375 million to invest in early-stage firms that develop high-impact technologies that can change lives. 

• ALX Oncology Announces Upcoming Virtual Investor Conference Participation in September 2021

  9/7/2021

  ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company developing therapies that block the CD47 checkpoint pathway, announced that Jaume Pons, Ph.D., Founder, President and Chief Executive Officer and other senior executives, will participate in two upcoming virtual investor conferences.

• ALX Oncology Reports Second Quarter 2021 Financial Results and Provides Clinical Development and Operational Highlights

  8/12/2021

  ALX Oncology Holdings Inc., (“ALX Oncology”) (Nasdaq: ALXO) a clinical-stage immuno-oncology company developing therapies that block the CD47 checkpoint pathway, today reported financial results for the second quarter ended June 30, 2021 and provided clinical development and operational highlights.

• ALX Oncology Announces First Patient Dosed in ASPEN-04, a Phase 2 Study of ALX148 in Combination with KEYTRUDA® (pembrolizumab) and Chemotherapy for the Treatment of Patients with Advanced Head and Neck Squamous Cell Carcinoma

  7/28/2021

  ALX Oncology Holdings Inc. in partnership with Merck, known as MSD outside the United States and Canada, announced the first patient has been dosed in the Phase 2 ASPEN-04 study evaluating the combination of ALX148, a next generation CD47 blocker, with KEYTRUDA®, Merck’s anti-PD-1 therapy, and standard chemotherapy for the treatment of patients with advanced head and neck squamous cell carcinoma.

• ALX Oncology Announces New Data from ASPEN-01, the Phase 1b Study of ALX148, Showing Robust Objective Response in Patients with Gastric or Gastroesophageal Junction Cancer

  7/3/2021

  ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company developing therapies to block the CD47 checkpoint mechanism, announced the presentation of updated clinical data from its ongoing ASPEN-01 trial evaluating ALX148 in combination with trastuzumab and chemotherapy for the treatment of gastric or gastroesophageal junction cancer.